Dabigatran etexilate: A novel oral direct thrombin inhibitor

American Journal of Health-System Pharmacy

Volumn 68, Issue 16, 2011, Pages 1506-1519

  Blommel, Matthew L ^a,b   Blommel, Amy L ^c  

^a West Virginia Center for Drug and Health Information   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

^c Monongahela Valley Hospital   (United States)

Author keywords

Absorption; Anticoagulants; Dabigatran etexilate; Dosage; Drug administration; Drugs; Mechanism of action; Metabolism; Pharmacokinetics; Stroke; Toxicity

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ATORVASTATIN; CARBOXYLESTERASE; CLARITHROMYCIN; CYTOCHROME P450; DABIGATRAN; DABIGATRAN ETEXILATE; DICLOFENAC; DIGOXIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; QUINIDINE; VERAPAMIL; WARFARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTICOAGULATION; AREA UNDER THE CURVE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; BRAIN HEMORRHAGE; CARDIAC PATIENT; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; CONSTIPATION; CREATININE CLEARANCE; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CONJUGATION; DRUG CONTRAINDICATION; DRUG COST; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG FORMULATION; DRUG INDICATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EMBOLISM; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; GLUCURONIDATION; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMOSTASIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; KIDNEY FUNCTION; LOW DRUG DOSE; LUNG EMBOLISM; MAINTENANCE DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PARTIAL THROMBOPLASTIN TIME; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SIDE EFFECT; STROKE; SURGICAL PATIENT; TIME TO MAXIMUM PLASMA CONCENTRATION; TOTAL HIP PROSTHESIS; TOTAL KNEE REPLACEMENT; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT WITHDRAWAL; VENOUS THROMBOEMBOLISM; VOMITING;

EID: 80051875192     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100348     Document Type: Review

References (41)

1. Oger E. Incidence of venous thromboembolism: A community-based study in Western France. Thromb Haemost. 2000; 83:657-660 (Pubitemid 30248509)
2. Spencer F.A., Emery C., Lessard D. et al. The Worcester Venous Thromboembolism study: A population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2006; 21:722-727 (Pubitemid 43973557)
3. Brass L., Krumholz L., Scinto J. et al. Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med. 1998; 158:2093-2100 (Pubitemid 28482091)
4. Olsson SB, for the Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation: Randomised controlled trial. Lancet. 2003; 362:1691-1698
5. Albers G.W., Diener H.C., Frison L. et al. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: A randomized trial. JAMA. 2005; 293:690-698
6. The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): A randomised controlled trial. Lancet. 2006; 367:1903-1912
7. Ansell J., Hirsh J., Hylek E. et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest. 2008; 133(suppl):160S-198S. (Pubitemid 351892967)
8. Rudd K.M., Dier J.G. Comparison of two different models of anticoagulation services with usual medical care. Pharmacotherapy. 2010; 30:330-338
9. Harrison L., McGinnis J., Crouther M. et al. Assessment of outpatient treatment of deep-vein thrombosis with lowmolecular- weight heparin. Arch Intern Med. 1998; 158:2001-2003 (Pubitemid 28465624)
10. Skedgal C., Goeree R., Pleasance S. et al. The cost-effectiveness of extendedduration antithrombotic prophylaxis after total hip arthroplasty. J Bone Joint Surg Am. 2007; 89:819-828 (Pubitemid 46564288)
11. Bergquist D., Jonsson B. Cost-effectiveness of prolonged administration of a low molecular weight heparin for the prevention of deep venous thrombosis following total hip replacement. Value Health. 1999; 2:288-294
12. Gulseth M.P. Ximelagatran: An orally active direct thrombin inhibitor. Am J Health-Syst Pharm. 2005; 62:1451-1467 (Pubitemid 41008859)
13. Pradaxa (dabigatran etexilate) package insert. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; 2010.
14. Boehringer Ingelheim. Dabigatran etexilate recommended for approval in atrial fibrillation for stroke prevention in Europe. www.boehringeringelheim. com/news/news-releases/ press-releases/2011/15-april-2011- dabigatran.html (accessed 2011 Apr 18).
15. Stangier J., Rathgen K., Stahle H. et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007; 64:292-303. (Pubitemid 47283865)
16. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor Dabigatran etexilate. Clin Pharmacokinet. 2008; 47:285-295 (Pubitemid 351508116)
17. Hauel N.H., Nar H., Priepke H. et al. Structure-based design of novel potent nonpeptide thrombin inhitibors. J Med Chem. 2002; 45:1757-1766 (Pubitemid 34415371)
18. Weitz J.I. Factor Xa or thrombin: Is thrombin a better target? J Thromb Hemost. 2007; 5(suppl 1):65-67 (Pubitemid 46958818)
19. Baetz B.E., Spinler S.A. Dabigatran etexilate: An oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Pharmacotherapy. 2008; 28:1354-1373
20. Blech S., Ebner T., Ludwig-Schwellinger E. et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008; 36:386-399 (Pubitemid 351185753)
21. Boehringer Ingelheim International GmbH. Pradaxa: summary of product characteristics. www.pradaxa.com/ HCP/Home/prescribing-information/ index.jsp (accessed 2010 May 20).
22. Garcia D., Libby E., Crowther M.A. The new oral anticoagulants. Blood. 2010; 115:15-20.
23. Bellamy L., Rosencher N., Eriksson B. Adherence to a new oral anticoagulant treatment prescription: dabigatran etexilate. Patient Prefer Adherence. 2009; 3:173-177
24. Stangier J., Eriksson B.I., Dahl O.E. et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005; 45:555-563 (Pubitemid 40562946)
25. Stangier J., Stahle H., Rathgen K. et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008; 47:47-59. (Pubitemid 350260888)
26. Stangier J., Rathgen K., Stahle H. et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: An open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010; 49:259-268
27. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139-1151
28. White H.D., Gruber M., Feyzi J. et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulation control. Arch Intern Med. 2007; 167:239-245
29. Gage B.F. Can we rely on RE-LY? N Engl J Med. 2009; 361:1200- 1202Editorial.
30. Eriksson B.I., Dahl O.E., Buller H.R. et al. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: The BISTRO II randomized trial. J Thromb Haemost. 2005; 3:103-111 (Pubitemid 41647122)
31. Eriksson B.I., Dahl O.E., Rosencher N. et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: A randomised, double-blind, non-inferiority trial. Lancet. 2007; 370:949-956 (Pubitemid 47393577)
32. Eriksson B.I., Dahl O.E., Rosencher N. et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: The RE-MODEL randomized trial. J Thromb Haemost. 2007; 5:2178-2185 (Pubitemid 47617868)
33. Ginsberg J.S., Davidson B.L., Comp P.C. et al. Oral thrombin inhibitor dabigatran etexilate vs. North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty. 2009; 24:1-9.
34. Schulman S., Kearon C., Kakkar A.K. et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361:2342-2352
35. Fiessinger J.N., Huisman M.V., Davidson B.L. et al. Ximelagatran vs low molecular weight heparin and warfarin for the treatment of deep vein thrombosis: A randomized trial. JAMA. 2005; 293:681-689 (Pubitemid 40216038)
36. Stangier J., Stahle H., Rathgen K. Effect of food and pantoprazole on the bioavailability of the direct thrombin inhibitor dabigatran in healthy subjects. J Thromb Haemost. 2005; 3(suppl 1):P1612. Abstract.
37. Marchetti S., Mazzanti R., Beijnen J.H. et al. Clinical relevance of drug-drug and herb-drug interactions mediated by the ABC transporter ABCB1 (MDR1, Pglycoprotein). Oncologist. 2007; 12:927-941 (Pubitemid 47359135)
38. Williams D.A. Drug metabolism. In: Lemke TL, Williams DA, eds. Foye's principles of medicinal chemistry. 6th ed. Baltimore: Lippincott Williams & Wilkins; 2008:253-326.
39. Wang Y.H., Li Y., Yang S.L. et al. Classification of substrates and inhibitors of p-glycoprotein using unsupervised machine learning approach. J Chem Inf Model. 2005; 45:750-757 (Pubitemid 40795178)
40. Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Newly identified events in the RE-LY trial. N Engl J Med. 2010; 363:1875-1876
41. Food and Drug Administration. Pradaxa (dabigatran etexilate mesylate) capsules: special storage and handling requirements. www.fda.gov/Safety/ MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm249005.htm (accessed 2011 Apr 19).